Supplementary Figure S1 from Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer

Autor: Bertolt Kreft, Karl Ziegelbauer, Rolf Jautelat, Heiner Apeler, Gabriele Leder, Jan Tebbe, Sherif El Sheikh, Rudolf Beier, Frank Dittmer, Jörg Müller, Oliver von Ahsen, Joachim Schuhmacher, Kirk Mclean, Patricia E. Carrigan, Christoph Kneip, Sven Golfier, Claudia Lange, Carol Pena, Beatrix Stelte-Ludwig, Charlotte Kopitz, Hans-Georg Lerchen, Lars Linden, Jörg Willuda
Rok vydání: 2023
DOI: 10.1158/1535-7163.22503556
Popis: Synthesis of C4.4A-ADC (A), Active metabolites resulting from intracellular degradation of C4.4A-ADC (B), Activity of the C4.4A-ADC metabolites (C), Range of drug-to-antibody ratio (D), and Purity and aggregate content of the ADC (E).
Databáze: OpenAIRE